Amicus Therapeutics, Inc. Forecast, price target & analysts
Amicus Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Amicus Therapeutics, Inc. Classifications & Recommendation:
Amicus Therapeutics, Inc. Price Target
| Target Price | $15.30 |
| Price | $6.10 |
| Potential |
150.82%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Amicus Therapeutics, Inc. 2026 .
The average Amicus Therapeutics, Inc. target price is $15.30.
This is
150.82%
register free of charge
$23.10
278.69%
register free of charge
$9.09
49.02%
register free of charge
|
|
| A rating was issued by 18 analysts: 14 Analysts recommend Amicus Therapeutics, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Amicus Therapeutics, Inc. stock has an average upside potential 2026 of
150.82%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 528.30 | 633.09 |
| 32.29% | 19.84% | |
| EBITDA Margin | 8.07% | 14.00% |
| 147.23% | 73.58% | |
| Net Margin | -10.62% | -4.35% |
| 72.02% | 59.04% |
14 Analysts have issued a sales forecast Amicus Therapeutics, Inc. 2025 . The average Amicus Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Amicus Therapeutics, Inc. EBITDA forecast 2025. The average Amicus Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Amicus Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Amicus Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.18 | -0.09 |
| 64.71% | 50.00% | |
| P/E | negative | |
| EV/Sales | 3.19 |
14 Analysts have issued a Amicus Therapeutics, Inc. forecast for earnings per share. The average Amicus Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Amicus Therapeutics, Inc....
Current Amicus Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 02 2025 |
| UBS |
Locked
➜
Locked
|
Locked | May 02 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jan 15 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 02 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
May 02 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jan 15 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Dec 13 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
